<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144816" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Strategies for Individualizing Pulmonary Hypertension Treatment to Ensure Optimal Patient Outcomes (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Azzo</surname>
            <given-names>Lance</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Yasmine S.</given-names>
          </name>
          <aff>Assistant Clinical Professor of Medicine, Vanderbilt Univ. School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaqar</surname>
            <given-names>Sarosh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lance Azzo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmine Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarosh Vaqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144816.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pulmonary hypertension (PH) is a disease characterized by elevated pulmonary artery pressure (mean pulmonary artery pressure [mPAP] &#x02265;20 mmHg at rest with a pulmonary vascular resistance [PVR] &#x02265;3 Wood units).<xref ref-type="bibr" rid="article-144816.r1">[1]</xref>&#x000a0;The World Health Organization (WHO) classifies patients with PH into five groups based on etiology:<xref ref-type="bibr" rid="article-144816.r1">[1]</xref><xref ref-type="bibr" rid="article-144816.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Group 1&#x02014;Pulmonary arterial hypertension (PAH)</p>
          </list-item>
          <list-item>
            <p>Group 2&#x02014;PH due to left heart disease</p>
          </list-item>
          <list-item>
            <p>Group 3&#x02014;PH due to chronic lung disease (CLD) and/or hypoxemia</p>
          </list-item>
          <list-item>
            <p>Group 4&#x02014;PH due to pulmonary artery obstructions</p>
          </list-item>
          <list-item>
            <p>Group 5&#x02014;PH due to unclear multifactorial mechanisms</p>
          </list-item>
        </list>
        <p>The term PAH is used to describe those included in group 1, while the term PH is used when describing all five groups.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;PAH is a rare disorder found in 15 to 50 persons per million within the United States (US) and Europe.<xref ref-type="bibr" rid="article-144816.r4">[4]</xref>&#x000a0;</p>
        <p>While schistosomiasis appears to be the most common cause of PAH worldwide, registry data in regions of the world without endemic schistosomiasis report that over half of cases of PAH are idiopathic (IPAH) and up to 10% are heritable PAH (HPAH).<xref ref-type="bibr" rid="article-144816.r5">[5]</xref><xref ref-type="bibr" rid="article-144816.r6">[6]</xref><xref ref-type="bibr" rid="article-144816.r7">[7]</xref>&#x000a0;Among the other associated etiologies of PAH, connective tissue disease and congenital heart disease appear most common.<xref ref-type="bibr" rid="article-144816.r5">[5]</xref><xref ref-type="bibr" rid="article-144816.r6">[6]</xref><xref ref-type="bibr" rid="article-144816.r8">[8]</xref>&#x000a0;</p>
        <p>Compared with other groups of PH, IPAH affects younger adults.<xref ref-type="bibr" rid="article-144816.r9">[9]</xref>&#x000a0;In contrast, in older populations, group 1 PAH is relatively uncommon. In one series, only 15% of 246 adults with PH older than 65 years had PAH, most frequently in association with connective tissue disease.<xref ref-type="bibr" rid="article-144816.r10">[10]</xref>&#x000a0;</p>
        <p>Although both men and women can have PAH, women are more likely to be affected (female: male ratio ranges from 1.7 to 4.8&#x000a0;to 1.0) and symptomatic.<xref ref-type="bibr" rid="article-144816.r9">[9]</xref><xref ref-type="bibr" rid="article-144816.r11">[11]</xref>&#x000a0;One US registry reported a PAH predominance among White patients (73% of registered cases), but PAH was also seen in Black Americans (12%), Hispanic Americans (9%), and Asian Americans (3%).<xref ref-type="bibr" rid="article-144816.r9">[9]</xref></p>
        <p>Individuals suspected of having PH should undergo extensive diagnostic testing.<xref ref-type="bibr" rid="article-144816.r12">[12]</xref>&#x000a0;The purpose of diagnostic testing is to confirm the diagnosis of PH and identify the etiology so that appropriate treatment can be administered.<xref ref-type="bibr" rid="article-144816.r13">[13]</xref>&#x000a0;</p>
        <p>Unfortunately, the diagnosis is often delayed because the presenting features of PH are frequently attributed incorrectly to age, deconditioning, or a coexisting or alternate medical condition.<xref ref-type="bibr" rid="article-144816.r14">[14]</xref>&#x000a0;As a result, PH is often not suspected until symptoms become severe.<xref ref-type="bibr" rid="article-144816.r15">[15]</xref>&#x000a0;Many patients have symptoms of PH for longer than one year before it is recognized.<xref ref-type="bibr" rid="article-144816.r15">[15]</xref>&#x000a0;This is particularly prevalent among patients younger than 35 years.<xref ref-type="bibr" rid="article-144816.r15">[15]</xref></p>
        <p>In the current era of PAH management, 1-year survival rates have increased to 86% to 90% from 65% in the 1980s, and average long-term survival has increased to 6 years from 2.8 years. Research advances focused on phenotyping and understanding the pathophysiology of PAH at a cellular and genetic level has opened the doors to possibilities of precision medicine and the development of therapies that may prevent or reverse pulmonary vascular remodeling.<xref ref-type="bibr" rid="article-144816.r16">[16]</xref></p>
      </sec>
      <sec id="article-144816.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Diagnosis of Pulmonary Arterial Hypertension</bold>
</p>
        <p>Signs and symptoms of PH (including group 1 PAH) are nonspecific.<xref ref-type="bibr" rid="article-144816.r17">[17]</xref><xref ref-type="bibr" rid="article-144816.r18">[18]</xref>&#x000a0;Individuals typically present with exertional dyspnea and fatigue that progresses over time until severe PH with overt right ventricular failure develops.<xref ref-type="bibr" rid="article-144816.r19">[19]</xref></p>
        <p>Common signs and symptoms of PH include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dyspnea and fatigue&#x02014;The most common initial symptoms of PH are exertional dyspnea, lethargy, and fatigue due to an inadequate increase in cardiac output during exercise.<xref ref-type="bibr" rid="article-144816.r20">[20]</xref><xref ref-type="bibr" rid="article-144816.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Symptoms of right ventricular failure, which develop as PH progresses, include the following:
<list list-type="bullet"><list-item><p>Exertional chest pain&#x02014;Exertional chest pain (i.e., angina) is usually due to subendocardial hypoperfusion caused by increased right ventricular wall stress and myocardial oxygen demand. However, it is occasionally caused by compression of the left main coronary artery by an enlarged pulmonary artery, particularly in patients with a pulmonary artery trunk at least 40 mm in diameter.<xref ref-type="bibr" rid="article-144816.r22">[22]</xref><xref ref-type="bibr" rid="article-144816.r23">[23]</xref><xref ref-type="bibr" rid="article-144816.r24">[24]</xref></p></list-item><list-item><p>Exertional syncope&#x02014;Exertional syncope occurs due to an insufficient increase in cardiac output during activity or reflex bradycardia from mechanoreceptor activation in the right ventricle.<xref ref-type="bibr" rid="article-144816.r25">[25]</xref></p></list-item><list-item><p>Weight gain from edema&#x02014;Peripheral edema is due to right ventricular failure, increased right-sided filling pressures, and extracellular volume expansion.<xref ref-type="bibr" rid="article-144816.r25">[25]</xref></p></list-item><list-item><p>Anorexia and/or abdominal pain and swelling&#x02014;Anorexia and/or abdominal pain in the right upper quadrant is due to passive hepatic congestion.<xref ref-type="bibr" rid="article-144816.r25">[25]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Uncommon symptoms of PH include cough, hemoptysis, and hoarseness. The hoarseness is caused by compression of the left recurrent laryngeal nerve by a dilated main pulmonary artery (Ortner syndrome), resulting in unilateral vocal cord paralysis.<xref ref-type="bibr" rid="article-144816.r25">[25]</xref></p>
        <p>As PH progresses, the following signs of right ventricular failure may be evident:<xref ref-type="bibr" rid="article-144816.r25">[25]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Jugular venous pressure (JVP) abnormalities&#x02014;The JVP is typically elevated in patients with PH. Initially, a prominent <italic toggle="yes">a</italic> wave is seen, while a prominent <italic toggle="yes">v</italic> wave indicates significant tricuspid regurgitation and often severe right ventricular failure.</p>
          </list-item>
          <list-item>
            <p>Right-sided auscultatory findings that are augmented with inspiration may be heard, including:
<list list-type="bullet"><list-item><p>A right-sided third or fourth heart sound (i.e., a gallop) in association with a left parasternal heave or a downward subxiphoid thrust</p></list-item><list-item><p>Wide splitting of the second heart sound</p></list-item><list-item><p>A holosystolic murmur of tricuspid regurgitation and, in more severe cases, a diastolic pulmonic regurgitation murmur</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly, a pulsatile or tender liver, peripheral edema, ascites, and pleural effusion (i.e., signs of severe decompensated right ventricular failure)</p>
          </list-item>
        </list>
        <p>The electrocardiogram (ECG) may provide supportive evidence of PH, but a normal ECG does not exclude the diagnosis of PH.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;Signs of right ventricular hypertrophy or strain include right axis deviation, an R wave/S wave ratio greater than one in lead V1, incomplete or complete right bundle branch block, and/or increased P wave amplitude in lead II (P pulmonale) due to right atrial enlargement.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;</p>
        <p>While right ventricular hypertrophy has insufficient sensitivity and specificity to&#x000a0;serve as a screening tool, prolongation of the QRS complex and QTc suggest severe disease.<xref ref-type="bibr" rid="article-144816.r27">[27]</xref><xref ref-type="bibr" rid="article-144816.r28">[28]</xref></p>
        <p>In 90% of individuals with IPAH, the chest radiograph is abnormal at the time of diagnosis.<xref ref-type="bibr" rid="article-144816.r29">[29]</xref>&#x000a0;Right ventricular enlargement and right atrial dilatation may be seen with a chest radiograph.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;Imaging can also help narrow the differential among the causes of PH.<xref ref-type="bibr" rid="article-144816.r30">[30]</xref></p>
        <p>Once PH is suspected, the initial test of choice is transthoracic echocardiography (TTE), which then determines the sequence of subsequent testing.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;The&#x000a0;TTE evaluates the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Estimated pulmonary artery pressure using the tricuspid regurgitant jet velocity (TRV)</p>
          </list-item>
          <list-item>
            <p>The assessment of right ventricular size, wall thickness, and function</p>
          </list-item>
          <list-item>
            <p>The potential contribution of left-sided heart disease to PH<xref ref-type="bibr" rid="article-144816.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>Guidelines issued by the European Society of Cardiology (ESC)/European Respiratory Society (ERS) propose using the peak TRV together with echocardiographic signs of PH.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref></p>
        <table-wrap id="article-144816.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1: Echocardiographic Probability of PH[26]</title>
          </caption>
          <table style="width: 440.554px; height: 301px;">
            <tbody>
              <tr style="height: 61px;">
                <td style="width: 99px; height: 61px;" rowspan="1" colspan="1">
<p><bold>Peak TRV (m/s)</bold></p>
</td>
                <td style="width: 134px; height: 61px;" rowspan="1" colspan="1">
<p><bold>Presence of Other Echocardiographic PH Signs*</bold></p>
</td>
                <td style="width: 134px; height: 61px;" rowspan="1" colspan="1">
<p><bold>Echocardiographic Probability of PH</bold></p>
</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 99px; height: 48px;" rowspan="1" colspan="1">
<p>&#x02264;2.8 or not measurable</p>
</td>
                <td style="width: 134px; height: 48px;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="width: 134px; height: 48px;" rowspan="1" colspan="1">
<p>Low</p>
</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 99px; height: 48px;" rowspan="1" colspan="1">
<p>&#x02264;2.8 or not measurable</p>
</td>
                <td style="width: 134px; height: 48px;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="width: 134px; height: 48px;" rowspan="1" colspan="1">
<p>Intermediate</p>
</td>
              </tr>
              <tr style="height: 35.3551px;">
                <td style="width: 99px; height: 35.3551px;" rowspan="1" colspan="1">
<p>2.9 to 3.4</p>
</td>
                <td style="width: 134px; height: 35.3551px;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="width: 134px; height: 35.3551px;" rowspan="1" colspan="1">
<p>Intermediate</p>
</td>
              </tr>
              <tr style="height: 35.3551px;">
                <td style="width: 99px; height: 35.3551px;" rowspan="1" colspan="1">
<p>2.9 to 3.4</p>
</td>
                <td style="width: 134px; height: 35.3551px;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="width: 134px; height: 35.3551px;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 99px; height: 35px;" rowspan="1" colspan="1">
<p>&#x0003e;3.4</p>
</td>
                <td style="width: 134px; height: 35px;" rowspan="1" colspan="1">
<p>Not required</p>
</td>
                <td style="width: 134px; height: 35px;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-144816.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2: Echocardiographic Signs Suggesting PH[26]</title>
          </caption>
          <table style="width: 824.768px;">
            <tbody>
              <tr>
                <td style="width: 252px;" rowspan="1" colspan="1">
<p><bold>A: The Ventricles* </bold></p>
</td>
                <td style="width: 279px;" rowspan="1" colspan="1">
<p><bold>B: Pulmonary Artery*</bold></p>
</td>
                <td style="width: 267.768px;" rowspan="1" colspan="1">
<p><bold>C: Inferior Vena Cava and Right Atrium* </bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 252px;" rowspan="1" colspan="1">
<p>Right ventricle/left ventricle basal diameter ratio &#x0003e;1.0</p>
</td>
                <td style="width: 279px;" rowspan="1" colspan="1">
<p>Right ventricular outflow Doppler acceleration time &#x0003c;105 msec and/or mid-systolic notching</p>
</td>
                <td style="width: 267.768px;" rowspan="1" colspan="1">
<p>Inferior cava diameter &#x0003e;21 mm with decreased inspiratory collapse (&#x0003c;50% with a sniff or &#x0003c;20% with quiet inspiration)</p>
</td>
              </tr>
              <tr>
                <td style="width: 252px;" rowspan="1" colspan="1">
<p>Flattening of the interventricular septum (left ventricular eccentricity index &#x0003e;1.1 in systole and/or diastole)</p>
</td>
                <td style="width: 279px;" rowspan="1" colspan="1">
<p>Early diastolic pulmonary regurgitation velocity &#x0003e;2.2 m/sec</p>
</td>
                <td style="width: 267.768px;" rowspan="1" colspan="1">
<p>Right atrial area (end-systole) &#x0003e;18 cm</p>
</td>
              </tr>
              <tr>
                <td style="width: 252px;" rowspan="1" colspan="1">
</td>
                <td style="width: 279px;" rowspan="1" colspan="1">
<p>Pulmonary artery diameter &#x0003e;25 mm</p>
</td>
                <td style="width: 267.768px;" rowspan="1" colspan="1">
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>* Echocardiographic signs from at least two different categories (A/B/C) from the list should be present to alter the level of echocardiographic probability of PH.</p>
        <p>The recommended plan per the ESC/ERS guidelines for further patient investigation based on the echocardiographic probability of PH is shown in <bold>Table 3 </bold>for symptomatic patients.</p>
        <table-wrap id="article-144816.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3: Diagnostic Management Suggested According to Echocardiographic Probability of PH in Patients With Symptoms Compatible With PH, With or Without Risk Factors for PAH or Chronic Thromboembolic Pulmonary Hypertension (CTEPH)[26]</title>
          </caption>
          <table style="width: 824.152px;">
            <tbody>
              <tr style="height: 48px;">
                <td style="width: 208px; height: 48px;" rowspan="1" colspan="1">
<p><bold>Echocardiographic Probability of PH</bold></p>
</td>
                <td style="width: 331px; height: 48px;" rowspan="1" colspan="1">
<p><bold>Without Risk Factors or Associated Conditions for PAH or CTEPH</bold></p>
</td>
                <td style="width: 261.152px; height: 48px;" rowspan="1" colspan="1">
<p><bold>With Risk Factors or Associated Conditions for PAH or CTEPH</bold></p>
</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 208px; height: 48px;" rowspan="1" colspan="1">
<p>Low</p>
</td>
                <td style="width: 331px; height: 48px;" rowspan="1" colspan="1">
<p>An alternative diagnosis should be considered.</p>
</td>
                <td style="width: 261.152px; height: 48px;" rowspan="1" colspan="1">
<p>Echocardiography follow-up should be considered.</p>
</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 208px; height: 48px;" rowspan="1" colspan="1">Intermediate</td>
                <td style="width: 331px; height: 48px;" rowspan="1" colspan="1">
<p>Alternative diagnosis and echocardiography follow-up should be considered. Further investigation of PH may be considered.</p>
</td>
                <td style="width: 261.152px; height: 48px;" rowspan="1" colspan="1">Further assessment of PH (including RHC) should be considered.</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 208px; height: 48px;" rowspan="1" colspan="1">
<p>High</p>
</td>
                <td style="width: 331px; height: 48px;" rowspan="1" colspan="1">
<p>Further investigation of PH (including RHC) is recommended.</p>
</td>
                <td style="width: 261.152px; height: 48px;" rowspan="1" colspan="1">
<p>Further investigation of PH (including RHC) is recommended.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>RHC&#x02014;right heart catheterization</p>
        <table-wrap id="article-144816.table3" position="float" orientation="portrait">
          <caption>
            <title>Table 4: Hemodynamic Definitions of Pre- and Post-Capillary PH[1]</title>
          </caption>
          <table style="width: 478.973px;">
            <tbody>
              <tr>
                <td style="width: 207px;" rowspan="1" colspan="1">
<p><bold>Definitions </bold></p>
</td>
                <td style="width: 150px;" rowspan="1" colspan="1">
<p><bold>Characteristics </bold></p>
</td>
                <td style="width: 98.9732px;" rowspan="1" colspan="1">
<p><bold>Clinical Groups of PH</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 207px;" rowspan="1" colspan="1">
<p>Pre-capillary PH</p>
</td>
                <td style="width: 150px;" rowspan="1" colspan="1">
<p>mPAP &#x0003e;20 mmHg</p>
<p>PAWP &#x02264;15 mmHg</p>
<p>PVR &#x02265;3 Wood units</p>
</td>
                <td style="width: 98.9732px;" rowspan="1" colspan="1">
<p>1, 3, 4, and 5</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px;" rowspan="1" colspan="1">
<p>Isolated post-capillary PH (IpcPH)</p>
</td>
                <td style="width: 150px;" rowspan="1" colspan="1">
<p>mPAP &#x0003e;20 mmHg</p>
<p>PAWP &#x0003e;15 mmHg</p>
<p>PVR &#x0003c;3 Wood units</p>
</td>
                <td style="width: 98.9732px;" rowspan="1" colspan="1">
<p>2 and 5</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px;" rowspan="1" colspan="1">
<p>Combined pre- and post-capillary PH (CpcPH)</p>
</td>
                <td style="width: 150px;" rowspan="1" colspan="1">
<p>mPAP &#x0003e;20 mmHg</p>
<p>PAWP &#x0003e;15 mmHg</p>
<p>PVR &#x02265;3 Wood units</p>
</td>
                <td style="width: 98.9732px;" rowspan="1" colspan="1">
<p>2 and 5</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>PAWP&#x02014;pulmonary arterial wedge pressure</p>
        <p>The diagnosis of group 1 PAH requires RHC to demonstrate an mPAP &#x02265;20 mmHg at rest and a PVR &#x02265;3 Wood units.<xref ref-type="bibr" rid="article-144816.r31">[31]</xref>&#x000a0;Several additional criteria to exclude the remaining categories of PH must also be met:<xref ref-type="bibr" rid="article-144816.r32">[32]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Mean pulmonary capillary wedge pressure (PCWP) &#x02264;15 mmHg (to exclude PH due to left heart disease [i.e., group 2 PH])</p>
          </list-item>
          <list-item>
            <p>CLDs and other causes of hypoxemia are mild or absent (to exclude PH owing to CLD or hypoxemia [i.e., group 3 PH])</p>
          </list-item>
          <list-item>
            <p>Venous thromboembolic disease and pulmonary artery obstructions are absent (to exclude group 4 PH)</p>
          </list-item>
          <list-item>
            <p>Certain miscellaneous disorders are absent, including systemic disorders (e.g., sarcoidosis, chronic renal insufficiency), hematologic disorders (e.g., myeloproliferative diseases, chronic hemolytic anemias), and metabolic disorders (e.g., glycogen storage disease). The purpose is to exclude PH with unclear multifactorial mechanisms (group 5 PH)</p>
          </list-item>
        </list>
        <p>Below are all the conditions associated with group 1 PAH that should be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p>IPAH and HPAH (1.1 and 1.2)</p>
          </list-item>
          <list-item>
            <p>Drugs and toxins (1.3)</p>
          </list-item>
          <list-item>
            <p>PAH associated with (1.4):</p>
          </list-item>
          <list-item>
            <p>Connective tissue disease</p>
          </list-item>
          <list-item>
            <p>Human immunodeficiency virus (HIV) infection</p>
          </list-item>
          <list-item>
            <p>Portal hypertension</p>
          </list-item>
          <list-item>
            <p>Congenital heart disease</p>
          </list-item>
          <list-item>
            <p>Schistosomiasis</p>
          </list-item>
          <list-item>
            <p>Long-term responders to calcium channel blocker (CCB) therapy (1.5)</p>
          </list-item>
          <list-item>
            <p>PAH with overt features of venous/capillary involvement (1.6)</p>
          </list-item>
          <list-item>
            <p>Persistent PH of the newborn (1.7)<xref ref-type="bibr" rid="article-144816.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Risk Assessment</bold>
</p>
        <p>Patients with PAH should be referred to a specialized center for evaluation and management. A comprehensive assessment is required since no single variable provides sufficient diagnostic and prognostic information. Risk stratification determines the initial PAH regimen chosen and is also used to determine disease progression and response to therapy. To determine PAH risk assessment, a multidimensional approach is needed. <bold>Table 5</bold>, which is derived from the ESC/ERS guidelines, lists the variables that are most frequently used in PH centers.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref></p>
        <table-wrap id="article-144816.table4" position="float" orientation="portrait">
          <caption>
            <title>Table 5: Risk Assessment in PAH[26]</title>
          </caption>
          <table style="width: 764px;">
            <tbody>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p><bold>Determinants of Prognosis (Estimated 1-Year Mortality)</bold></p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p><bold>Low risk &#x0003c;5%</bold></p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p><bold>Intermediate Risk (5%&#x000a0;to 10%)</bold></p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p><bold>High Risk &#x0003e;10%</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Clinical signs of right heart failure</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>Absent</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>Absent</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>Present</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Progression of symptoms</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>Slow</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>Rapid</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Syncope</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>Occasional syncope</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>Repeated syncope</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>WHO FC</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>I, II</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>III</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>IV</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>6MWD</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>&#x0003e;440 m</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>165&#x000a0;to 440 m</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>&#x0003c;165 m</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Cardiopulmonary exercise testing</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>Peak VO&#x0003e;15 ml/min/kg</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>Peak VO 11&#x000a0;to 15 ml/min/kg</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>Peak VO&#x0003c;11 ml/min/kg</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>NT-proBNP plasma levels</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>BNP &#x0003c;50 ng/l</p>
<p>NT-proBNP &#x0003c;300 ng/l</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>BNP 50&#x000a0;to 300 ng/l</p>
<p>NT-proBNP 300-1400 ng/l</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>BNP &#x0003e;300 ng/l</p>
<p>NT-proBNP &#x0003e;1400 ng/l</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Imaging (echocardiography, CMR imaging)</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>RA area &#x0003c;18 cm</p>
<p>No pericardial effusion</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>RA area 18&#x000a0;to 26 cm</p>
<p>No or minimal pericardial effusion</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>RA area &#x0003e;26 cm</p>
<p>Pericardial effusion</p>
</td>
              </tr>
              <tr>
                <td style="width: 214.875px;" rowspan="1" colspan="1">
<p>Hemodynamics</p>
</td>
                <td style="width: 184.125px;" rowspan="1" colspan="1">
<p>RAP &#x0003c;8 mmHg</p>
<p>CI &#x02265;2.5 l/min/m</p>
<p>SvO&#x0003e;65%</p>
</td>
                <td style="width: 183px;" rowspan="1" colspan="1">
<p>RAP 8&#x000a0;to 14 mmHg</p>
<p>CI 2.0-2.4 l/min/m</p>
<p>SvO60-65%</p>
</td>
                <td style="width: 151px;" rowspan="1" colspan="1">
<p>RAP &#x0003e;14 mmHg</p>
<p>CI &#x0003c;2.0 l/min/m</p>
<p>SvO&#x0003c;60%</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>6MWD&#x02014;6-minute walking distance</p>
        <p>BNP&#x02014;brain natriuretic peptide</p>
        <p>CI&#x02014;cardiac index</p>
        <p>CMR&#x02014;cardiac magnetic resonance</p>
        <p>FC&#x02014;functional class</p>
        <p>NT-proBNP&#x02014;N-terminal pro-brain natriuretic peptide</p>
        <p>RA&#x02014;right atrium</p>
        <p>RAP&#x02014;right atrial pressure</p>
        <p>SvO&#x02014;mixed venous oxygen saturation</p>
        <p>VO&#x02014;oxygen consumption</p>
        <p>The goal of treatment is to bring all the patients&#x02019; variables to the low-risk column in <bold>Table 5</bold>, often through treatment escalation or switching of therapy.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref></p>
        <table-wrap id="article-144816.table5" position="float" orientation="portrait">
          <caption>
            <title>Table 6: WHO FC for PH[33]</title>
          </caption>
          <table style="width: 669.554px;">
            <tbody>
              <tr>
                <td style="width: 32px;" rowspan="1" colspan="1">
<p><bold>Class</bold></p>
</td>
                <td style="width: 622.554px;" rowspan="1" colspan="1">
<p><bold>WHO FC</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 32px;" rowspan="1" colspan="1">
<p>I</p>
</td>
                <td style="width: 622.554px;" rowspan="1" colspan="1">
<p>Patients with PH but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue or dyspnea, chest pain, or heart syncope.</p>
</td>
              </tr>
              <tr>
                <td style="width: 32px;" rowspan="1" colspan="1">
<p>II</p>
</td>
                <td style="width: 622.554px;" rowspan="1" colspan="1">
<p>Patients with PH resulting in slight limitation of physical activity;&#x000a0;they are comfortable at rest. Ordinary physical activity results in undue fatigue or dyspnea, chest pain, or heart syncope.</p>
</td>
              </tr>
              <tr>
                <td style="width: 32px;" rowspan="1" colspan="1">
<p>III</p>
</td>
                <td style="width: 622.554px;" rowspan="1" colspan="1">
<p>Patients with PH resulting in marked limitation of physical activity; they are comfortable at rest. Less than ordinary physical activity causes undue fatigue or dyspnea, chest pain, or heart syncope.</p>
</td>
              </tr>
              <tr>
                <td style="width: 32px;" rowspan="1" colspan="1">
<p>IV</p>
</td>
                <td style="width: 622.554px;" rowspan="1" colspan="1">
<p>Patients with a PH resulting in an inability to carry on any physical activity without symptoms; these patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by physical activity.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Several groups have proposed other models for risk stratification. These include the US Registry to Evaluate Early and Long-term PAH disease management (REVEAL), the Swedish PAH Registry (SPAHR), and the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), and the French pulmonary hypertension network (FPHN). Like the ESC/ERS approach, most of these models predict survival and involve a multidimensional approach that includes elements of clinical, biochemical (e.g., BNP), functional (e.g., exercise capacity, WHO FC), and hemodynamic parameters (echocardiography and pulmonary arterial catheter) that have prognostic significance.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref></p>
        <p>The 1-year survival of patients with newly diagnosed group 1 PAH may be predicted using a risk score derived from the REVEAL registry data. The risk score is the sum of points derived from clinical data, including group 1 subgroup, demographics, and comorbidities; FC, vital signs, 6MWD, and BNP level;&#x000a0;plus echocardiogram, pulmonary function tests, and RHC findings. Data were prospectively collected from 504 patients with a mean 6MWD of 308 meters, 62% of whom were classified as WHO FC III. Overall, 1-year survival correlated with risk score: 1 to 7 (95%), 8 (92%), 9 (89%), 10 to 11 (72%), and &#x02265;12 (66%). Although not agreed upon, a score of 1 or less is considered low-risk, a score between 2 and 9 is considered moderate-risk, and a score of 10 or greater is high-risk.<xref ref-type="bibr" rid="article-144816.r34">[34]</xref><xref ref-type="bibr" rid="article-144816.r35">[35]</xref><xref ref-type="bibr" rid="article-144816.r36">[36]</xref><xref ref-type="bibr" rid="article-144816.r37">[37]</xref></p>
        <p>The prognosis was reported using data from the COMPERA database. Patients were risk-stratified utilizing a model that incorporated WHO FC, 6MWD, BNP levels, RAP, CI, and SvO. Mortality rates in patients one year after diagnosis were 3% for low-risk patients, 10% for intermediate-risk patients, and 21% for high-risk patients.<xref ref-type="bibr" rid="article-144816.r38">[38]</xref></p>
        <p>These proposed models have limitations and must be used in conjunction with clinical assessment.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r39">[39]</xref></p>
        <p>Given the importance of risk stratification in managing patients with PAH, researchers have been investigating novel models to enhance the risk stratification approach. Recently, a 4-strata risk model categorizing PAH patients as low, intermediate-low, intermediate-high, or high risk has been proposed. This approach differs from the traditional 3-strata risk model (low risk, intermediate risk, high risk) proposed by the ESC/ERS. Studies have demonstrated that this 4-strata risk assessment method improves risk prediction, especially within the intermediate-risk category of patients with PAH. Additionally, this model has been shown to perform better at predicting survival and is more sensitive to change than the conventional 3-strata approach.<xref ref-type="bibr" rid="article-144816.r40">[40]</xref><xref ref-type="bibr" rid="article-144816.r41">[41]</xref></p>
        <p>
<bold>Current Treatment</bold>
</p>
        <p>PAH represents an imbalance between vasoconstrictors and proliferative mediators (e.g., endothelin-1) and vasodilators (e.g., nitric oxide, prostacyclin).<xref ref-type="bibr" rid="article-144816.r42">[42]</xref>&#x000a0;Three key therapeutic approaches target either the nitric oxide, endothelin-1, or prostacyclin pathways <bold>(Table 7)</bold>. The&#x000a0;emergence of targeted therapies for PAH has raised the 1-year survival rates to 91% and the 5-year&#x000a0;survival rates to 61% for newly diagnosed patients.<xref ref-type="bibr" rid="article-144816.r43">[43]</xref><xref ref-type="bibr" rid="article-144816.r44">[44]</xref></p>
        <p>The 4 US FDA-approved treatment classes for PAH include phosphodiesterase type 5 inhibitors (PDE5Is), oral endothelin-receptor antagonists (ERAs), prostacyclin pathway agents (PPAs), and soluble guanylate cyclase (sGC) stimulants.</p>
        <table-wrap id="article-144816.table6" position="float" orientation="portrait">
          <caption>
            <title>Table 7: PAH-Specific FDA-Approved Therapies[45]</title>
          </caption>
          <table style="width: 661.705px;">
            <tbody>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">
<p><bold>Class</bold></p>
</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p><bold>Agent</bold></p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p><bold>Administrative Route</bold></p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">
<p>PPAs</p>
</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Epoprostenol</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Continuous IV infusion via a central venous catheter</p>
</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 83px; height: 48px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 48px;" rowspan="1" colspan="1">
<p>Treprostinil</p>
</td>
                <td style="width: 278.705px; height: 48px;" rowspan="1" colspan="1">
<p>Continuous IV infusion via a central venous catheter or continuous SC infusion; inhaled; oral</p>
</td>
              </tr>
              <tr style="height: 38.3267px;">
                <td style="width: 83px; height: 38.3267px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 38.3267px;" rowspan="1" colspan="1">Iloprost</td>
                <td style="width: 278.705px; height: 38.3267px;" rowspan="1" colspan="1">Inhaled&#x000a0;</td>
              </tr>
              <tr style="height: 38.3267px;">
                <td style="width: 83px; height: 38.3267px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 38.3267px;" rowspan="1" colspan="1">Selexipag</td>
                <td style="width: 278.705px; height: 38.3267px;" rowspan="1" colspan="1">Oral; IV formulation is available for temporary use when unable to take oral therapy</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">
<p>ERAs</p>
</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Bosentan</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Ambrisentan</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Macitentan</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">
<p>sGC stimulants</p>
</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Riociguat</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">
<p>PDE5Is</p>
</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Sildenafil</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral; IV</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 83px; height: 35px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 278px; height: 35px;" rowspan="1" colspan="1">
<p>Tadalafil</p>
</td>
                <td style="width: 278.705px; height: 35px;" rowspan="1" colspan="1">
<p>Oral</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>IV&#x02014;intravenous</p>
        <p>SC&#x02014;subcutaneous</p>
        <p>According to the treatment algorithm proposed by the 6th World Symposium on Pulmonary Hypertension, select patients with PAH should undergo acute vasoreactivity testing (AVT) to identify the small subset of PAH patients (10%&#x000a0;to 20%) who may respond to CCB therapy.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;This includes patients with IPAH, HPAH, and drug/toxin-induced PAH (i.e., individuals who are most likely to be vasoreactive).<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;</p>
        <p>Patients with associated forms of PAH are rarely vasoreactive, and, as such, vasoreactive testing is not indicated.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r46">[46]</xref>&#x000a0;This includes patients with PAH due to connective tissue disease, congenital heart disease, HIV, portal hypertension, and schistosomiasis.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r46">[46]</xref>&#x000a0;For patients with PAH who are vasoreactive, the American College of Chest Physicians (ACCP) and the 6th World Symposium on Pulmonary Hypertension both recommend an initial trial of therapy with an oral CCB.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p>Improved survival was reported in an observational study of 64 patients with IPAH, which reported that the 5-year survival was greater among patients who received CCB therapy (primarily nifedipine) compared with a control group of patients (comprised non-vasoreactive IPAH patients and historical controls).<xref ref-type="bibr" rid="article-144816.r47">[47]</xref>&#x000a0;</p>
        <p>Another observational study of 557 patients with IPAH found that only 13% had a positive vasoreactivity test, and 54% of the vasoreactive patients with IPAH who received CCB therapy maintained functional improvement after one year.<xref ref-type="bibr" rid="article-144816.r48">[48]</xref>&#x000a0;Responders were more vasoreactive (i.e., had a greater decrease of mPAP during the vasoreactivity test) and had less severe disease at baseline.<xref ref-type="bibr" rid="article-144816.r48">[48]</xref></p>
        <p>The daily doses of these drugs that have shown efficacy in IPAH are relatively high: 120&#x02013;240 mg for nifedipine, 240&#x000a0;to 720 mg for diltiazem, and up to 20 mg for amlodipine.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref><xref ref-type="bibr" rid="article-144816.r45">[45]</xref>&#x000a0;Due to its potential negative inotropic effects, verapamil should be avoided.<xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p>Many of the adverse events (AEs) associated with CCBs are because of the potent systemic vasodilatory properties of CCBs (e.g., hypotension, peripheral edema).<xref ref-type="bibr" rid="article-144816.r49">[49]</xref><xref ref-type="bibr" rid="article-144816.r50">[50]</xref><xref ref-type="bibr" rid="article-144816.r49">[49]</xref>&#x000a0;Paradoxically, while pulmonary vasodilation from CCB therapy may reduce hypoxic vasoconstriction, loss of hypoxic vasoconstriction can worsen ventilation-perfusion mismatch and hypoxemia.<xref ref-type="bibr" rid="article-144816.r51">[51]</xref><xref ref-type="bibr" rid="article-144816.r52">[52]</xref>&#x000a0;CCBs may also be associated with deterioration of right ventricular function due to the negative inotropic effect of CCBs.<xref ref-type="bibr" rid="article-144816.r53">[53]</xref></p>
        <p>Individuals who respond to CCB therapy should be reassessed after 3&#x000a0;to 6 months of treatment.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;A poor response to therapy necessitates evaluation for non-CCB PAH-specific treatments.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p>For patients with PAH who are typically non-vasoreactive (e.g., connective tissue disease-PAH) and have not undergone vasoreactive testing, and for patients who are non-vasoreactive or are vasoreactive and have failed CCB therapy, PAH-specific therapy is indicated.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;The ACCP guidelines use the WHO FC to select suitable agents,&#x000a0;while the 6th World Symposium on Pulmonary Hypertension utilizes the allocation of PAH-specific therapy based upon high risk and low or intermediate-risk categories.<xref ref-type="bibr" rid="article-144816.r45">[45]</xref><xref ref-type="bibr" rid="article-144816.r3">[3]</xref></p>
        <p>PAH-specific therapy consistently improves hemodynamic measures, WHO FC, and the 6MWD.<xref ref-type="bibr" rid="article-144816.r54">[54]</xref><xref ref-type="bibr" rid="article-144816.r55">[55]</xref>&#x000a0;A meta-analysis of 21 randomized trials (3140 patients) found that therapy with a prostanoid, an ERA, or a PDE5I improved mortality compared with no therapy (1.5% vs. 3.8%; risk reduction [RR], 0.57; 95% confidence interval [CI], 0.35-0.92).<xref ref-type="bibr" rid="article-144816.r55">[55]</xref></p>
        <p>For treatment-na&#x000ef;ve PAH patients with WHO FC I symptoms, the ACCP guidelines suggest monitoring closely for disease progression to a functional level that warrants therapy (e.g., WHO FC II).<xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p>For patients with WHO FC II or III or who have low or intermediate risk PAH, both the ACCP guidelines and 6th World Symposium on Pulmonary Hypertension recommend dual combination therapy with an ERA (e.g., ambrisentan) and PDE5I (e.g., tadalafil) for most patients.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref><xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p><bold>Tadalafil plus ambrisentan</bold>&#x02014;A randomized trial (AMBITION) of 500 drug-na&#x000ef;ve patients with group 1 PAH (mostly idiopathic and connective tissue disease-related) with class II or III symptoms compared the combination of 10 mg of ambrisentan and 40 mg of tadalafil with either agent alone.<xref ref-type="bibr" rid="article-144816.r56">[56]</xref>&#x000a0;The combined regimen, administered on average for 18 months, resulted in a 50% reduction in the clinical failure rate (18% versus 31%) and improved exercise capacity (49 versus 24 meters).<xref ref-type="bibr" rid="article-144816.r56">[56]</xref>&#x000a0;The reduction in clinical failure rate was primarily driven by decreased hospitalizations for progressive PAH (which portends a poor prognosis) rather than by improved survival or WHO FC.<xref ref-type="bibr" rid="article-144816.r56">[56]</xref>&#x000a0;AEs (e.g., edema, headache, nasal congestion, anemia, syncope) were reported more frequently in those receiving combination therapy (45% vs. 30%), but rates of hypotension were similar.<xref ref-type="bibr" rid="article-144816.r56">[56]</xref></p>
        <p>Other combination oral regimens of dual therapy consisting of an ERA and a PDE5I are feasible options in patients not suited to the ambrisentan/tadalafil combination (e.g., contraindications to the drug or AEs).</p>
        <p><bold>Macitentan plus sildenafil&#x02014;</bold>The SERAPHIN trial compared the oral ERA, macitentan, with placebo in 250 patients with moderate-to-severe PAH; 85% of patients had IPAH or connective tissue disease-associated PAH, and the majority were FC II or III. Approximately 60% of patients were already on a PDE5I (i.e., combined therapy), mostly sildenafil, and 40% were treatment-na&#x000ef;ve (i.e., single-agent therapy with macitentan). Over a 2-year period, fewer patients treated with macitentan (3 mg or 10 mg daily) progressed or died on therapy (38% and 31%, respectively, vs. 46%). Exercise capacity and WHO FC also improved with macitentan treatment. This benefit was observed independent of whether patients were on combination or single-agent oral therapy for PAH.<xref ref-type="bibr" rid="article-144816.r57">[57]</xref><xref ref-type="bibr" rid="article-144816.r58">[58]</xref></p>
        <p><bold>Bosentan plus tadalafil</bold>&#x02014;The PHIRST trial randomly assigned 405 patients with mostly FC II and III PAH, half of whom were on bosentan, to receive tadalafil (2.5, 10, 20, or 40 mg) or placebo once daily for 16 weeks. Tadalafil (40 mg) significantly increased the 6MWD and the time to clinical worsening while also decreasing the incidence of clinical worsening and improving health-related quality of life (QoL).<xref ref-type="bibr" rid="article-144816.r59">[59]</xref></p>
        <p><bold>Bosentan plus sildenafil</bold>&#x02014;In a prospective study, the addition of sildenafil to bosentan in PAH patients who had developed clinical deterioration improved symptoms, exercise capacity, and WHO FC.<xref ref-type="bibr" rid="article-144816.r60">[60]</xref>&#x000a0;Improvement was more frequent and of greater magnitude in patients with IPAH than individuals with scleroderma-associated PAH.<xref ref-type="bibr" rid="article-144816.r60">[60]</xref>&#x000a0;In another study of patients failing monotherapy with either bosentan or sildenafil, the addition of either agent also resulted in improved FC and survival in those with IPAH compared with those with connective tissue-associated PAH.<xref ref-type="bibr" rid="article-144816.r61">[61]</xref></p>
        <p>According to the 6th World Symposium on Pulmonary Hypertension, single-agent oral therapy may be appropriate for patients with low- or intermediate-risk diseases who have a low-risk profile and for patients who have been stable on monotherapy for a prolonged period (e.g., 5 to 10 years).<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;</p>
        <p>Other possible indications include patients &#x0003e;75 years old with multiple risk factors for heart failure, individuals suspected to have pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis, patients with contraindications to combination therapy (e.g., severe liver disease), individuals with portopulmonary hypertension and HIV (i.e., patients who were not included in the combination trials), or patients who decline combination therapy.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;</p>
        <p>Per the ACCP guidelines, options for these patients include ERAs (i.e., ambrisentan, bosentan, macitentan), PDE5Is (i.e., sildenafil, tadalafil), and sGC stimulators (i.e., riociguat).<xref ref-type="bibr" rid="article-144816.r45">[45]</xref>&#x000a0;</p>
        <p>The choice of therapy may depend on several factors, including patient preferences, cost, route of administration, toxicity profile, comorbidities (e.g., liver failure, kidney failure), and potential drug interactions with other agents.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;For patients with WHO FC III (not WHO FC II) symptoms who have rapid progression or other markers of poor clinical diagnosis (e.g., echocardiographic evidence of severe right ventricular dilatation), the ACCP guidelines advise consideration of initial treatment with a parenteral prostanoid (i.e., IV epoprostenol or treprostinil, SC treprostinil).<xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p><bold>ERAs as a group&#x02014;</bold>In a meta-analysis of 16 randomized trials that compared ERAs with placebo in individuals with FC II/III, patients receiving ERAs had improved exercise capacity (mean increase of 25 m), FC (odds ratio [OR], 1.41; 95% CI, 1.16-1.70), and symptoms, and reduced odds of FC deterioration (OR, 0.43; 95% CI, 0.26-0.72). There was low certainty of the evidence of a possible reduction in mortality from ERA use (OR 0.78, 95% CI, 0.58-1.07).<xref ref-type="bibr" rid="article-144816.r62">[62]</xref></p>
        <p><bold>Ambrisentan&#x02014;</bold>Randomized placebo-controlled trials (e.g., ARIES-1, ARIES-2) of patients with moderate-to-severe IPAH and connective tissue disease-related PAH (mostly WHO FC II and III) consistently reported that ambrisentan, administered for up to 2 years, delayed disease progression and clinical worsening. Moreover, ambrisentan was associated with improved exercise tolerance, WHO FC, pulmonary vascular hemodynamics, and QoL.<xref ref-type="bibr" rid="article-144816.r63">[63]</xref><xref ref-type="bibr" rid="article-144816.r64">[64]</xref><xref ref-type="bibr" rid="article-144816.r65">[65]</xref></p>
        <p><bold>Bosentan</bold>&#x02014;Bosentan has been shown in individuals with group 1 PAH to delay clinical worsening and improve pulmonary vascular hemodynamics and exercise capacity.<xref ref-type="bibr" rid="article-144816.r66">[66]</xref><xref ref-type="bibr" rid="article-144816.r67">[67]</xref><xref ref-type="bibr" rid="article-144816.r68">[68]</xref><xref ref-type="bibr" rid="article-144816.r69">[69]</xref>&#x000a0;The mortality of bosentan-treated IPAH patients appears favorable compared with historical controls.<xref ref-type="bibr" rid="article-144816.r68">[68]</xref><xref ref-type="bibr" rid="article-144816.r70">[70]</xref></p>
        <p><bold>Macitentan&#x02014;</bold>In the aforementioned SERAPHIN trial that compared macitentan with placebo in 250 patients with moderate-to-severe PAH (mostly WHO FC II and III), the benefits that were observed in the patients taking combined therapy (e.g., slower disease progression and lower mortality, improved exercise tolerance) were also seen in a subgroup of patients who were on single-agent therapy with macitentan.<xref ref-type="bibr" rid="article-144816.r57">[57]</xref><xref ref-type="bibr" rid="article-144816.r58">[58]</xref></p>
        <p>The main AEs of ERAs are hepatotoxicity and peripheral edema.<xref ref-type="bibr" rid="article-144816.r57">[57]</xref><xref ref-type="bibr" rid="article-144816.r63">[63]</xref><xref ref-type="bibr" rid="article-144816.r64">[64]</xref><xref ref-type="bibr" rid="article-144816.r65">[65]</xref><xref ref-type="bibr" rid="article-144816.r67">[67]</xref><xref ref-type="bibr" rid="article-144816.r71">[71]</xref><xref ref-type="bibr" rid="article-144816.r72">[72]</xref>&#x000a0;Additionally, ERAs are also potent teratogens, requiring meticulous, double-method contraception if used by women with childbearing potential. Macitentan may also be complicated by nasopharyngitis and anemia.<xref ref-type="bibr" rid="article-144816.r57">[57]</xref>&#x000a0;</p>
        <p>Ambrisentan is contraindicated in patients with concurrent idiopathic pulmonary fibrosis (IPF); one randomized study reported that this agent was associated with an increased risk of IPF disease progression and hospitalizations.<xref ref-type="bibr" rid="article-144816.r73">[73]</xref></p>
        <p><bold>PDE5Is as a group</bold>&#x02014;A meta-analysis of 36 studies (2999 patients) reported that patients with group 1 PAH treated with PDE5Is were more likely to improve their WHO FC (OR, 8.59; 95% CI, 3.95-18.72) and less likely to die (OR, 0.088; 95% CI, 0.07-0.68).<xref ref-type="bibr" rid="article-144816.r74">[74]</xref></p>
        <p><bold>Sildenafil&#x02014;</bold>Sildenafil improves pulmonary hemodynamics and exercise capacity in individuals with group 1 PAH.<xref ref-type="bibr" rid="article-144816.r75">[75]</xref><xref ref-type="bibr" rid="article-144816.r76">[76]</xref><xref ref-type="bibr" rid="article-144816.r77">[77]</xref><xref ref-type="bibr" rid="article-144816.r78">[78]</xref>&#x000a0;The SUPER-1 trial randomly assigned 277 patients with group 1 PAH to receive sildenafil or placebo three times daily for 12 weeks.<xref ref-type="bibr" rid="article-144816.r75">[75]</xref>&#x000a0;The sildenafil group demonstrated significant improvement in hemodynamics and 6MWD, which persisted during one year of follow-up.<xref ref-type="bibr" rid="article-144816.r75">[75]</xref>&#x000a0;</p>
        <p>A follow-up, open-label 3-year extension trial (SUPER-2) reported persistent improvement in the 6MWD and WHO FC in 46% and 29% of patients, respectively.<xref ref-type="bibr" rid="article-144816.r79">[79]</xref>&#x000a0;The estimated 3-year survival rate was 79%.<xref ref-type="bibr" rid="article-144816.r79">[79]</xref></p>
        <p><bold>Tadalafil&#x02014;</bold>In the PHIRST-1 and -2 trials that included 405 PAH patients, half of whom were treatment na&#x000ef;ve, tadalafil increased the 6MWD and the time to clinical worsening when compared with placebo.<xref ref-type="bibr" rid="article-144816.r59">[59]</xref></p>
        <p>Common AEs of PDE5Is include headache, gastrointestinal (GI) upset, flushing, and muscle pain.</p>
        <p><bold>Riociguat</bold>&#x02014;Data have shown that riociguat improves outcomes for individuals with group 1 PAH. In trials of WHO FC II and III PAH patients (PATENT-1 and -2), half of whom were treatment-na&#x000ef;ve, riociguat improved exercise tolerance, PVR, symptoms, WHO FC, and time to clinical worsening for up to 2 years of treatment. Riociguat had a favorable safety profile and was well tolerated, with syncope as the most frequently reported AE (4% vs. 1%).<xref ref-type="bibr" rid="article-144816.r80">[80]</xref><xref ref-type="bibr" rid="article-144816.r81">[81]</xref></p>
        <p><bold>Parenteral prostanoids as a group&#x02014;</bold>Several parenteral prostanoids are available with the strongest evidence of efficacy in favor of IV epoprostenol. In a meta-analysis of 17 trials (765 patients with PAH), patients on prostacyclin agonists were&#x000a0;more than twice as likely to have improved WHO FC, 6MWD, and pulmonary hemodynamics compared with a control group of PAH patients (placebo, any other treatment, or usual care). Mortality improved in individuals receiving IV agents (OR, 0.29; 95% CI, 0.12-0.69).<xref ref-type="bibr" rid="article-144816.r82">[82]</xref></p>
        <p><bold>Epoprostenol</bold>&#x02014;In patients with PAH, IV epoprostenol consistently improves hemodynamic parameters and functional capacity.<xref ref-type="bibr" rid="article-144816.r82">[82]</xref><xref ref-type="bibr" rid="article-144816.r83">[83]</xref><xref ref-type="bibr" rid="article-144816.r84">[84]</xref>&#x000a0;The efficacy of IV epoprostenol was demonstrated in a trial that randomly assigned 81 patients with WHO FC III or IV IPAH (three-quarters and one-quarter, respectively) to receive IV epoprostenol as single-agent therapy or standard therapy (typically oral therapy) for 12 weeks.<xref ref-type="bibr" rid="article-144816.r85">[85]</xref>&#x000a0;Intravenous (IV) epoprostenol improved QoL, mPAP, PVR, and exercise capacity. A total of 8 patients died during the study, all of whom were in the standard therapy group.<xref ref-type="bibr" rid="article-144816.r85">[85]</xref></p>
        <p>AEs that may be associated with epoprostenol include jaw pain, diarrhea, and flushing. Central venous catheter infection may also occur and contribute to the morbidity and mortality of continuous epoprostenol therapy.<xref ref-type="bibr" rid="article-144816.r82">[82]</xref><xref ref-type="bibr" rid="article-144816.r86">[86]</xref></p>
        <p><bold>Treprostinil</bold>&#x02014;IV and SC treprostinil improve hemodynamic parameters, symptoms, exercise capacity, and possibly survival in patients with group 1 PAH.<xref ref-type="bibr" rid="article-144816.r87">[87]</xref><xref ref-type="bibr" rid="article-144816.r88">[88]</xref><xref ref-type="bibr" rid="article-144816.r89">[89]</xref>&#x000a0;The AEs of treprostinil are similar to those of epoprostenol.&#x000a0;The ACCP guidelines advise considering the addition of a parenteral or inhaled prostanoid for PAH patients with WHO FC III who have evidence of progression of their disease and/or markers of poor clinical prognosis despite treatment with 1 or 2 classes of oral therapies.<xref ref-type="bibr" rid="article-144816.r45">[45]</xref>&#x000a0;Several combinations involving parenteral or inhaled prostacyclin analogs have been shown to be beneficial in individuals with PAH.</p>
        <p><bold>Sildenafil plus epoprostenol</bold>&#x02014;A trial randomly assigned 267 patients with group 1 PAH receiving epoprostenol to have sildenafil or placebo added for 16 weeks. Most patients were WHO FC III at the beginning of the study. Compared with the placebo, the combination regimen was associated with improved hemodynamic parameters, exercise capacity, QoL, and time to clinical worsening.<xref ref-type="bibr" rid="article-144816.r90">[90]</xref></p>
        <p><bold>Bosentan plus epoprostenol</bold>&#x02014;A study (BREATHE-2 trial) randomly assigned 22 individuals with group 1 PAH receiving epoprostenol to have either bosentan or placebo added for 16 weeks. The dual therapy was associated with improved hemodynamic parameters, exercise capacity, and WHO FC compared with baseline.<xref ref-type="bibr" rid="article-144816.r91">[91]</xref></p>
        <p><bold>Inhaled treprostinil plus either bosentan or sildenafil</bold>&#x02014;In one trial (TRIUMPH), 235 patients with group 1 PAH who were deteriorating despite bosentan or sildenafil therapy were randomly assigned to receive the addition of either inhaled treprostinil or placebo for 12 weeks. The treprostinil group had a significant improvement in their 6MWD and QoL.<xref ref-type="bibr" rid="article-144816.r92">[92]</xref></p>
        <p><bold>Sildenafil plus inhaled iloprost</bold>&#x02014;Studies have demonstrated that in patients with group 1 PAH have reported that the addition of sildenafil to inhaled iloprost resulted in an improvement in exercise capacity, WHO FC, and hemodynamics.<xref ref-type="bibr" rid="article-144816.r93">[93]</xref></p>
        <p><bold>Bosentan plus inhaled iloprost</bold>&#x02014;A study showed that the combination of bosentan with inhaled iloprost resulted in a marked increase in exercise capacity.<xref ref-type="bibr" rid="article-144816.r94">[94]</xref>&#x000a0;For high-risk PAH patients, the 6th World Symposium on Pulmonary Hypertension recommends initial combination therapy that includes IV PPAs, with IV epoprostenol receiving the strongest recommendation.<xref ref-type="bibr" rid="article-144816.r3">[3]</xref>&#x000a0;In contrast, for WHO FC IV PAH patients who are willing and able to manage parenteral prostanoids, the ACCP suggests monotherapy with either IV epoprostenol, IV treprostinil, or SC treprostinil.<xref ref-type="bibr" rid="article-144816.r45">[45]</xref></p>
        <p>
<bold>Emerging Treatments</bold>
</p>
        <p>Several therapies are currently undergoing investigation in clinical trials for the treatment of PAH.</p>
        <p>Mutations in bone morphogenetic protein (BMP) receptor type 2 (BMPR2) play a known role in the pathogenesis of PAH.<xref ref-type="bibr" rid="article-144816.r95">[95]</xref>&#x000a0;BMP is a member of the transforming growth factor (TGF)-beta family of proteins.<xref ref-type="bibr" rid="article-144816.r96">[96]</xref>&#x000a0;Sotatercept acts as a ligand trap for members of the TGF-beta superfamily and restores the balance between the growth-promoting activin pathway and the growth-inhibiting BMP pathway.<xref ref-type="bibr" rid="article-144816.r97">[97]</xref>&#x000a0;</p>
        <p>A total of 2 doses of sotatercept (0.3 or 0.7 mg/kg subcutaneously every three weeks) were compared with placebo in a 24-week multicenter trial of 106 patients with PAH receiving standard therapy.<xref ref-type="bibr" rid="article-144816.r98">[98]</xref>&#x000a0;Sotatercept reduced the PVR by 145.8 and 239 dyne/sec/cm&#x000a0;for the 0.3 and 0.7 mg/kg dosing strategies, respectively. Exercise tolerance was also improved as measured by an increase in the 6MWD (29.4. [0.3 mg/kg] and 21.4 m [0.7 mg/kg]), and levels of BNP were also reduced. The most common AEs were headache, diarrhea, and peripheral edema. Of note, sotatercept resulted in thrombocytopenia and an increased hemoglobin level, and one patient in the sotatercept 0.7-mg group died from cardiac arrest.<xref ref-type="bibr" rid="article-144816.r98">[98]</xref></p>
        <p>Selonsertib is a first-in-class small-molecule (apoptosis signal-regulating kinase 1 [ASK1]) inhibitor developed to treat diseases with a high burden of oxidative stress, including PAH.<xref ref-type="bibr" rid="article-144816.r99">[99]</xref>&#x000a0;The randomized, double-blind, placebo-controlled phase 2 ARROW trial included 151 study participants.<xref ref-type="bibr" rid="article-144816.r100">[100]</xref>&#x000a0;All were aged 18 to 75 years and had a diagnosis of PAH. From December 2014 to November 2015, patients were stratified by PAH etiology and background therapy, and underwent random assignment to selonsertib 2 mg, selonsertib 6 mg, selonsertib 18 mg, or placebo administered once daily via tablet. The primary outcome was a change in PVR from baseline to 24 weeks, as measured by RHC. Mean change in PVR was 6 dynes/cm&#x000a0;in the placebo group, 35 dynes/cm&#x000a0;in the selonsertib 2-mg group (<italic toggle="yes">P</italic>&#x000a0;= .21), 28 dynes/cm&#x000a0;in the selonsertib 6-mg group (<italic toggle="yes">P</italic>&#x000a0;= .27) and &#x02013;21 dynes/cm&#x000a0;in the selonsertib 18-mg group (<italic toggle="yes">P</italic>&#x000a0;= .60).<xref ref-type="bibr" rid="article-144816.r100">[100]</xref>&#x000a0;Additionally, the investigators reported no improvement in secondary outcomes such as exercise capacity, symptom burden, or worsening clinical events.</p>
        <p>Ralinepag is a selective non-prostanoid prostacyclin receptor agonist formulated as an oral, extended-release tablet taken once daily.<xref ref-type="bibr" rid="article-144816.r101">[101]</xref>&#x000a0;In a phase 2 randomized placebo-controlled trial, ralinepag significantly reduced PVR compared with placebo (&#x02212;29.8%;&#x000a0;<italic toggle="yes">P</italic>&#x000a0;= .03) in 61 patients receiving mono- (41%) or dual- (59%) background therapy.<xref ref-type="bibr" rid="article-144816.r102">[102]</xref>&#x000a0;Ralinepag was initiated at a dose of 10 &#x003bc;g twice daily and titrated as tolerated over nine weeks to a maximum total daily dosage of 600 &#x003bc;g (300 &#x003bc;g twice daily). Reported AEs included headache, nausea, diarrhea, jaw pain, and flushing. This agent is currently undergoing investigation in ongoing clinical trials. (NCT03626688; NCT04084678)</p>
      </sec>
      <sec id="article-144816.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Pulmonary hypertension presents with nonspecific and progressive symptoms, which require a high degree of suspicion to make a timely diagnosis. Without treatment, PH and pulmonary arterial hypertension are progressive and fatal diseases. Risk stratification in patients with risk factors for this disease helps guide diagnostic studies and leads to improved clinical outcomes with early diagnosis.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;</p>
        <p>Risk stratification also determines the initial treatment regimen and helps in monitoring disease progression and response to therapy. As described above, PAH represents an imbalance between vasoconstrictors and proliferative mediators (e.g., endothelin-1) and vasodilators (e.g., nitric oxide, prostacyclin).<xref ref-type="bibr" rid="article-144816.r42">[42]</xref>&#x000a0;Targeted therapies for PAH have improved the 1-year survival rates to 91% and the 5-year&#x000a0;survival rates to 61%.<xref ref-type="bibr" rid="article-144816.r43">[43]</xref><xref ref-type="bibr" rid="article-144816.r44">[44]</xref>&#x000a0;</p>
        <p>Following guideline-recommended diagnostic algorithms and treatment regimens has helped achieve this improvement. Emerging treatments and ongoing clinical trials continue to expand treatment options for patients with refractory disease or those who cannot receive available therapies. As a result,&#x000a0;the prognosis of PAH with treatment is improving compared to other forms of PH. In the Giessen Pulmonary Hypertension Registry, patients with&#x000a0;chronic lung disease associated-PH (group 3) had worse survival compared with PAH, and patients with group 2 PH had similar survival rates to those with PAH.<xref ref-type="bibr" rid="article-144816.r103">[103]</xref></p>
      </sec>
      <sec id="article-144816.s4" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Individuals suspected of having PH require extensive diagnostic testing, including echocardiography, laboratory testing, cardiopulmonary functional testing, and cardiac catheterization, to make an accurate diagnosis.<xref ref-type="bibr" rid="article-144816.r12">[12]</xref>&#x000a0;Moreover, the clinical presentation of this disease is nonspecific, which often leads to a delay in diagnosis.<xref ref-type="bibr" rid="article-144816.r14">[14]</xref>&#x000a0;A&#x000a0;multidimensional approach and a&#x000a0;high degree of clinical suspicion are needed to optimize care.<xref ref-type="bibr" rid="article-144816.r26">[26]</xref>&#x000a0;</p>
        <p>Early referral to specialized centers can help make a timely diagnosis and improve clinical outcomes for this devastating disease. Once the diagnosis is made, a multimodal interprofessional approach to treatment is required to achieve the best possible outcomes. A specialty-trained nurse is necessary to help educate the patients about the etiology of their disease and emphasize medical compliance with therapy. A clinical pharmacist specializing in the treatment of PAH is an integral part of the team as they help ensure intolerable adverse outcomes do not occur with these therapies.&#x000a0;The pharmacist's role is critical in maintaining adequate dosing, preventing drug interactions, and ensuring compliance by the patient for the duration of the treatment.&#x000a0;</p>
        <p>An integrated interprofessional team can improve clinical symptoms, exercise tolerance, and long-term survival for these patients.[Level 5]</p>
      </sec>
      <sec id="article-144816.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144816&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144816">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144816/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144816">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144816.s6">
        <title>References</title>
        <ref id="article-144816.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30545968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassoun</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Arterial Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>16</day>
            <volume>385</volume>
            <issue>25</issue>
            <fpage>2361</fpage>
            <page-range>2361-2376</page-range>
            <pub-id pub-id-type="pmid">34910865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Moiseeva</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
            </person-group>
            <article-title>Risk stratification and medical therapy of pulmonary arterial hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30545971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beshay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of pulmonary arterial hypertension.</article-title>
            <source>Respir Med</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>171</volume>
            <fpage>106099</fpage>
            <pub-id pub-id-type="pmid">32829182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chaouat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertocchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yaici</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weitzenblum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chabot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dromer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reynaud-Gaubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haloun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hachulla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension in France: results from a national registry.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>May</month>
            <day>01</day>
            <volume>173</volume>
            <issue>9</issue>
            <fpage>1023</fpage>
            <page-range>1023-30</page-range>
            <pub-id pub-id-type="pmid">16456139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Raskob</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Krichman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldkircher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.</article-title>
            <source>Chest</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-87</page-range>
            <pub-id pub-id-type="pmid">19837821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An epidemiological study of pulmonary arterial hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-9</page-range>
            <pub-id pub-id-type="pmid">17360728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>BX</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
            </person-group>
            <article-title>Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era.</article-title>
            <source>Chest</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>140</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-309</page-range>
            <pub-id pub-id-type="pmid">21330386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Krichman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Raskob</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Wason</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldkircher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.</article-title>
            <source>Chest</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-37</page-range>
            <pub-id pub-id-type="pmid">20558556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pugh</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sivarajan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hemnes</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Causes of pulmonary hypertension in the elderly.</article-title>
            <source>Chest</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>146</volume>
            <issue>1</issue>
            <fpage>159</fpage>
            <page-range>159-166</page-range>
            <pub-id pub-id-type="pmid">24480915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Escribano-Subias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pepke-Zaba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suissa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension: epidemiology and registries.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>24</day>
            <volume>62</volume>
            <issue>25 Suppl</issue>
            <fpage>D51</fpage>
            <page-range>D51-9</page-range>
            <pub-id pub-id-type="pmid">24355642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ashrith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sandeep</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation, Diagnosis, and Classification of Pulmonary Hypertension.</article-title>
            <source>Methodist Debakey Cardiovasc J</source>
            <year>2021</year>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <page-range>86-91</page-range>
            <pub-id pub-id-type="pmid">34326927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hambly</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alawfi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension: diagnostic approach and optimal management.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Aug</month>
            <day>09</day>
            <volume>188</volume>
            <issue>11</issue>
            <fpage>804</fpage>
            <page-range>804-812</page-range>
            <pub-id pub-id-type="pmid">27141034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-57</page-range>
            <pub-id pub-id-type="pmid">29915733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivarsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kjellstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>12</volume>
            <fpage>21501327211029241</fpage>
            <pub-id pub-id-type="pmid">34219509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshwal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sulica</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Advances in the management of pulmonary arterial hypertension.</article-title>
            <source>J Investig Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>1270</fpage>
            <page-range>1270-1280</page-range>
            <pub-id pub-id-type="pmid">34580123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiely</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lawrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Screening strategies for pulmonary arterial hypertension.</article-title>
            <source>Eur Heart J Suppl</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>Suppl K</issue>
            <fpage>K9</fpage>
            <page-range>K9-K20</page-range>
            <pub-id pub-id-type="pmid">31857796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braganza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solverson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janovcik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Varughese</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Thakrar</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Hirani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Helmersen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weatherald</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Evaluation of the Diagnostic&#x000a0;Accuracy of the Physical Examination for Pulmonary Hypertension.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>May</month>
            <volume>155</volume>
            <issue>5</issue>
            <fpage>982</fpage>
            <page-range>982-990</page-range>
            <pub-id pub-id-type="pmid">30826305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients.</article-title>
            <source>Am J Manag Care</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3 Suppl</issue>
            <fpage>S35</fpage>
            <page-range>S35-S41</page-range>
            <pub-id pub-id-type="pmid">33710842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Runo</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Loyd</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Primary pulmonary hypertension.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>May</month>
            <day>03</day>
            <volume>361</volume>
            <issue>9368</issue>
            <fpage>1533</fpage>
            <page-range>1533-44</page-range>
            <pub-id pub-id-type="pmid">12737878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Primary pulmonary hypertension.</article-title>
            <source>Thorax</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>12</issue>
            <fpage>1107</fpage>
            <page-range>1107-18</page-range>
            <pub-id pub-id-type="pmid">10567632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mesquita</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ikari</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>369</fpage>
            <page-range>369-74</page-range>
            <pub-id pub-id-type="pmid">15006585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension.</article-title>
            <source>Chest</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>1412</fpage>
            <page-range>1412-5</page-range>
            <pub-id pub-id-type="pmid">11591592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Silvestry</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>DeNofrio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Axel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palevsky</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension.</article-title>
            <source>Am J Cardiol</source>
            <year>1999</year>
            <month>Mar</month>
            <day>15</day>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>984</fpage>
            <page-range>984-6, A10</page-range>
            <pub-id pub-id-type="pmid">10190427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bhattacharya</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <chapter-title>Right Ventricular Hypertrophy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">29763051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez Sanchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klepetko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Zompatori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>M</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jan</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-119</page-range>
            <pub-id pub-id-type="pmid">26320113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
            </person-group>
            <article-title>Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>374</fpage>
            <page-range>374-380</page-range>
            <pub-id pub-id-type="pmid">21778258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Thenappan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Thisted</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Childers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>10</day>
            <volume>167</volume>
            <issue>3</issue>
            <fpage>669</fpage>
            <page-range>669-76</page-range>
            <pub-id pub-id-type="pmid">22459397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dantzker</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ayres</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bergofsky</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Detre</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Goldring</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Koerner</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Primary pulmonary hypertension. A national prospective study.</article-title>
            <source>Ann Intern Med</source>
            <year>1987</year>
            <month>Aug</month>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-23</page-range>
            <pub-id pub-id-type="pmid">3605900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remy-Jardin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ryerson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schiebler</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>ANC</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Alderson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haramati</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Thistlethwaite</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Beek</surname>
                <given-names>EJR</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society.</article-title>
            <source>Radiology</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>298</volume>
            <issue>3</issue>
            <fpage>531</fpage>
            <page-range>531-549</page-range>
            <pub-id pub-id-type="pmid">33399507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsallem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sternbach</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Adigopula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vu</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Zamanian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schnittger</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McConnell</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Addressing the Controversy of Estimating Pulmonary Arterial Pressure by Echocardiography.</article-title>
            <source>J Am Soc Echocardiogr</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-102</page-range>
            <pub-id pub-id-type="pmid">26691401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.</article-title>
            <source>JAMA Cardiol</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>1</volume>
            <issue>9</issue>
            <fpage>1056</fpage>
            <page-range>1056-1065</page-range>
            <pub-id pub-id-type="pmid">27851839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical insights into the pathogenesis of primary pulmonary hypertension.</article-title>
            <source>Chest</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>114</volume>
            <issue>3 Suppl</issue>
            <fpage>237S</fpage>
            <page-range>237S-241S</page-range>
            <pub-id pub-id-type="pmid">9741575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lavender</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Feenstra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horrigan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kermeen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kotlyar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McWilliams</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thakkar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whitford</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wrobel</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Validation of the REVEAL 2.0&#x000a0;Risk Score With the Australian and New&#x000a0;Zealand Pulmonary Hypertension Registry Cohort.</article-title>
            <source>Chest</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <page-range>162-172</page-range>
            <pub-id pub-id-type="pmid">31563497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Foreman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pasta</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Selej</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>156</volume>
            <issue>2</issue>
            <fpage>323</fpage>
            <page-range>323-337</page-range>
            <pub-id pub-id-type="pmid">30772387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Foreman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>354</fpage>
            <page-range>354-362</page-range>
            <pub-id pub-id-type="pmid">21680644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gressin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lemari&#x000e9;</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Muros-Le Rouzic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Validation of two predictive models for survival in pulmonary arterial hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>152</fpage>
            <page-range>152-64</page-range>
            <pub-id pub-id-type="pmid">25837032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Eichstaedt</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Spiesshoefer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vizza</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Vonk-Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Opitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JSR</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Huscher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pittrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.</article-title>
            <source>Eur Respir J</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28775047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pudasaini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension.</article-title>
            <source>BMC Pulm Med</source>
            <year>2018</year>
            <month>Oct</month>
            <day>16</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <pub-id pub-id-type="pmid">30326867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boucly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weatherald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Savale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Groote</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pr&#x000e9;vot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chaouat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Horeau-Langlard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bourdin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jutant</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Beurnier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jevnikar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ja&#x000ef;s</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.</article-title>
            <source>Eur Respir J</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>59</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">34737227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pausch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Huscher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pittrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staehler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vizza</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Opitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JSR</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ewert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaemmerer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kabitz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Skowasch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Milger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Halank</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilkens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seyfarth</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dumitrescu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tsangaris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vonk-Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klose</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Claussen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">34737226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Potoka</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gladwin</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension: the clinical syndrome.</article-title>
            <source>Circ Res</source>
            <year>2014</year>
            <month>Jun</month>
            <day>20</day>
            <volume>115</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-30</page-range>
            <pub-id pub-id-type="pmid">24951762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhardwaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for pulmonary arterial hypertension.</article-title>
            <source>J Thorac Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>Suppl 14</issue>
            <fpage>S1767</fpage>
            <page-range>S1767-S1781</page-range>
            <pub-id pub-id-type="pmid">31632754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farber</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Poms</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Muros-Le Rouzic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Five-Year outcomes of patients enrolled in the REVEAL Registry.</article-title>
            <source>Chest</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>1043</fpage>
            <page-range>1043-54</page-range>
            <pub-id pub-id-type="pmid">26066077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klinger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bossone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duvall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fagan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frantsve-Hawley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Sederstrom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-586</page-range>
            <pub-id pub-id-type="pmid">30660783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Savale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Natali</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ja&#x000ef;s</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Herve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.</article-title>
            <source>Eur Heart J</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>15</issue>
            <fpage>1898</fpage>
            <page-range>1898-907</page-range>
            <pub-id pub-id-type="pmid">20543192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Jul</month>
            <day>09</day>
            <volume>327</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-81</page-range>
            <pub-id pub-id-type="pmid">1603139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ja&#x000ef;s</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ioos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Herv&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.</article-title>
            <source>Circulation</source>
            <year>2005</year>
            <month>Jun</month>
            <day>14</day>
            <volume>111</volume>
            <issue>23</issue>
            <fpage>3105</fpage>
            <page-range>3105-11</page-range>
            <pub-id pub-id-type="pmid">15939821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palevsky</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Chronic cor pulmonale. Etiology and management.</article-title>
            <source>JAMA</source>
            <year>1990</year>
            <month>May</month>
            <day>02</day>
            <volume>263</volume>
            <issue>17</issue>
            <fpage>2347</fpage>
            <page-range>2347-53</page-range>
            <pub-id pub-id-type="pmid">2182919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hallemans</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naeije</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mols</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lejeune</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>130</volume>
            <issue>4</issue>
            <fpage>612</fpage>
            <page-range>612-6</page-range>
            <pub-id pub-id-type="pmid">6091508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Walmrath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schermuly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Temmesfeld-Wollbruck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>160</volume>
            <issue>2</issue>
            <fpage>600</fpage>
            <page-range>600-7</page-range>
            <pub-id pub-id-type="pmid">10430735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Voswinckel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reichenberger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haredza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karada&#x0015f;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schermuly</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2004</year>
            <month>Oct</month>
            <day>06</day>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>1488</fpage>
            <page-range>1488-96</page-range>
            <pub-id pub-id-type="pmid">15464333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yushak</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>890</fpage>
            <page-range>890-901</page-range>
            <pub-id pub-id-type="pmid">6491082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The value of approved therapies for pulmonary arterial hypertension.</article-title>
            <source>Am Heart J</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>153</volume>
            <issue>6</issue>
            <fpage>889</fpage>
            <page-range>889-90</page-range>
            <pub-id pub-id-type="pmid">17540187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palazzini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bacchi-Reggiani</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Branzi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.</article-title>
            <source>Eur Heart J</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>394</fpage>
            <page-range>394-403</page-range>
            <pub-id pub-id-type="pmid">19155250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barber&#x000e0;</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Vonk-Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gillies</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <collab>AMBITION Investigators</collab>
            </person-group>
            <article-title>Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>27</day>
            <volume>373</volume>
            <issue>9</issue>
            <fpage>834</fpage>
            <page-range>834-44</page-range>
            <pub-id pub-id-type="pmid">26308684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pulido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adzerikho</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Jansa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Le Brun</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mittelholzer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Perchenet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sastry</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <collab>SERAPHIN Investigators</collab>
            </person-group>
            <article-title>Macitentan and morbidity and mortality in pulmonary arterial hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Aug</month>
            <day>29</day>
            <volume>369</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-18</page-range>
            <pub-id pub-id-type="pmid">23984728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Jansa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Le Brun</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perchenet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sastry</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1711</fpage>
            <page-range>1711-20</page-range>
            <pub-id pub-id-type="pmid">26493786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beardsworth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frumkin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group</collab>
            </person-group>
            <article-title>Tadalafil therapy for pulmonary arterial hypertension.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Jun</month>
            <day>09</day>
            <volume>119</volume>
            <issue>22</issue>
            <fpage>2894</fpage>
            <page-range>2894-903</page-range>
            <pub-id pub-id-type="pmid">19470885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathai</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Housten-Harris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zaiman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassoun</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-75</page-range>
            <pub-id pub-id-type="pmid">17079256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palazzini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bachetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mazzanti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gotti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bacchi Reggiani</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>414</fpage>
            <page-range>414-21</page-range>
            <pub-id pub-id-type="pmid">26022952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Endothelin receptor antagonists for pulmonary arterial hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Mar</month>
            <day>26</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD004434</fpage>
            <pub-id pub-id-type="pmid">33765691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e9;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Zwicke</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Naeije</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Ambrisentan therapy for pulmonary arterial hypertension.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>Aug</month>
            <day>02</day>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-35</page-range>
            <pub-id pub-id-type="pmid">16053970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Roecker</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dufton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wiens</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <collab>Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group</collab>
            </person-group>
            <article-title>Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.</article-title>
            <source>Circulation</source>
            <year>2008</year>
            <month>Jun</month>
            <day>10</day>
            <volume>117</volume>
            <issue>23</issue>
            <fpage>3010</fpage>
            <page-range>3010-9</page-range>
            <pub-id pub-id-type="pmid">18506008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Widlitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beckmann</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Camanga</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alfie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.</article-title>
            <source>Chest</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-4</page-range>
            <pub-id pub-id-type="pmid">15249447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rainisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bodin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Oct</month>
            <day>06</day>
            <volume>358</volume>
            <issue>9288</issue>
            <fpage>1119</fpage>
            <page-range>1119-23</page-range>
            <pub-id pub-id-type="pmid">11597664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Galie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leconte</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Landzberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Bosentan therapy for pulmonary arterial hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Mar</month>
            <day>21</day>
            <volume>346</volume>
            <issue>12</issue>
            <fpage>896</fpage>
            <page-range>896-903</page-range>
            <pub-id pub-id-type="pmid">11907289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rainisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Survival with first-line bosentan in patients with primary pulmonary hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-9</page-range>
            <pub-id pub-id-type="pmid">15684287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.</article-title>
            <source>Chest</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>247</fpage>
            <page-range>247-54</page-range>
            <pub-id pub-id-type="pmid">12853530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Endothelin receptor antagonists in pulmonary arterial hypertension.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2004</year>
            <month>Jun</month>
            <day>16</day>
            <volume>43</volume>
            <issue>12 Suppl S</issue>
            <fpage>62S</fpage>
            <page-range>62S-67S</page-range>
            <pub-id pub-id-type="pmid">15194180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Oudiz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Galie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dufton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Despain</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.</article-title>
            <source>Chest</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <page-range>122-129</page-range>
            <pub-id pub-id-type="pmid">18812445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Alto</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on the use of ambrisentan in pulmonary arterial hypertension.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>331</fpage>
            <page-range>331-43</page-range>
            <pub-id pub-id-type="pmid">22933513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>O'Riordan</surname>
                <given-names>TG</given-names>
              </name>
              <collab>ARTEMIS-IPF Investigators*</collab>
            </person-group>
            <article-title>Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2013</year>
            <month>May</month>
            <day>07</day>
            <volume>158</volume>
            <issue>9</issue>
            <fpage>641</fpage>
            <page-range>641-9</page-range>
            <pub-id pub-id-type="pmid">23648946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase 5 inhibitors for pulmonary hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>31</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD012621</fpage>
            <pub-id pub-id-type="pmid">30701543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parpia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Branzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kurzyna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <collab>Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group</collab>
            </person-group>
            <article-title>Sildenafil citrate therapy for pulmonary arterial hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Nov</month>
            <day>17</day>
            <volume>353</volume>
            <issue>20</issue>
            <fpage>2148</fpage>
            <page-range>2148-57</page-range>
            <pub-id pub-id-type="pmid">16291984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schulze-Neick</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Magee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.</article-title>
            <source>Heart</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>E4</fpage>
            <pub-id pub-id-type="pmid">10908271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil in primary pulmonary hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Nov</month>
            <day>02</day>
            <volume>343</volume>
            <issue>18</issue>
            <fpage>1342</fpage>
            <pub-id pub-id-type="pmid">11183578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pepke-Zaba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collings</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.</article-title>
            <source>Chest</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">18187744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Oakes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Layton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serdarevic-Pehar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>SUPER-2 Study Group</collab>
            </person-group>
            <article-title>Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.</article-title>
            <source>Chest</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>140</volume>
            <issue>5</issue>
            <fpage>1274</fpage>
            <page-range>1274-1283</page-range>
            <pub-id pub-id-type="pmid">21546436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Langleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fritsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>1303</fpage>
            <page-range>1303-13</page-range>
            <pub-id pub-id-type="pmid">25614164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jansa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Kilpatrick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Langleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fritsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nikkho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2016</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>361</fpage>
            <page-range>361-71</page-range>
            <pub-id pub-id-type="pmid">27067479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yeoh</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Fothergill</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Prostacyclin for pulmonary arterial hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD012785</fpage>
            <pub-id pub-id-type="pmid">31042010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.</article-title>
            <source>Ann Intern Med</source>
            <year>1994</year>
            <month>Sep</month>
            <day>15</day>
            <volume>121</volume>
            <issue>6</issue>
            <fpage>409</fpage>
            <page-range>409-15</page-range>
            <pub-id pub-id-type="pmid">8053614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Herv&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rainisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2002</year>
            <month>Aug</month>
            <day>21</day>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>780</fpage>
            <page-range>780-8</page-range>
            <pub-id pub-id-type="pmid">12204511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>McGoon</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Bourge</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Koerner</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Langleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Murali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uretsky</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>J&#x000f6;bsis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Blackburn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shortino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>JW</given-names>
              </name>
              <collab>Primary Pulmonary Hypertension Study Group</collab>
            </person-group>
            <article-title>A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Feb</month>
            <day>01</day>
            <volume>334</volume>
            <issue>5</issue>
            <fpage>296</fpage>
            <page-range>296-301</page-range>
            <pub-id pub-id-type="pmid">8532025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinojosa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cruz-Utrilla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cristo Ropero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Medrano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arribas-Ynsaurriaga</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Escribano-Subias</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Complications associated with peripherally inserted central catheters and Hickman&#x02122; in patients with advanced pulmonary hypertension treated with intravenous prostanoids.</article-title>
            <source>Respir Med</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>189</volume>
            <fpage>106649</fpage>
            <pub-id pub-id-type="pmid">34673343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Widlitz</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Krichman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>683</fpage>
            <page-range>683-8</page-range>
            <pub-id pub-id-type="pmid">16537868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Galie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naeije</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jeffs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arneson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.</article-title>
            <source>Eur Respir J</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>1195</fpage>
            <page-range>1195-203</page-range>
            <pub-id pub-id-type="pmid">16899485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poms</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
            </person-group>
            <article-title>One-year experience with intravenous treprostinil for pulmonary arterial hypertension.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>889</fpage>
            <page-range>889-96</page-range>
            <pub-id pub-id-type="pmid">23953817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Collings</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cossons</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <collab>PACES Study Group</collab>
            </person-group>
            <article-title>Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2008</year>
            <month>Oct</month>
            <day>21</day>
            <volume>149</volume>
            <issue>8</issue>
            <fpage>521</fpage>
            <page-range>521-30</page-range>
            <pub-id pub-id-type="pmid">18936500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boonstra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.</article-title>
            <source>Eur Respir J</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <page-range>353-9</page-range>
            <pub-id pub-id-type="pmid">15358690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Channick</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Voswinckel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rubenfire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>May</month>
            <day>04</day>
            <volume>55</volume>
            <issue>18</issue>
            <fpage>1915</fpage>
            <page-range>1915-22</page-range>
            <pub-id pub-id-type="pmid">20430262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schermuly</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiedemann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreckel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Enke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>02</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>158</fpage>
            <page-range>158-64</page-range>
            <pub-id pub-id-type="pmid">12849677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Taha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bekjarova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gatzke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spiekerkoetter</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.</article-title>
            <source>Eur Respir J</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>330</fpage>
            <page-range>330-4</page-range>
            <pub-id pub-id-type="pmid">12952269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teichert-Kuliszewska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kutryk</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kuliszewski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Karoubi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Courtman</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zucco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Granton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.</article-title>
            <source>Circ Res</source>
            <year>2006</year>
            <month>Feb</month>
            <day>03</day>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-17</page-range>
            <pub-id pub-id-type="pmid">16357305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkbride</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bruinsma</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Blobe</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.</article-title>
            <source>J Biol Chem</source>
            <year>2008</year>
            <month>Mar</month>
            <day>21</day>
            <volume>283</volume>
            <issue>12</issue>
            <fpage>7628</fpage>
            <page-range>7628-37</page-range>
            <pub-id pub-id-type="pmid">18184661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yung</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Augur</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SSJ</given-names>
              </name>
              <name>
                <surname>Bocobo</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Dinter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Troncone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>McNeil</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Southwood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poli de Frias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Sako</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pearsall</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Quisel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.</article-title>
            <source>Sci Transl Med</source>
            <year>2020</year>
            <month>May</month>
            <day>13</day>
            <volume>12</volume>
            <issue>543</issue>
            <pub-id pub-id-type="pmid">32404506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JSR</given-names>
              </name>
              <name>
                <surname>Gomberg-Maitland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Escribano Subias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Manimaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>de Oliveira Pena</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Badesch</surname>
                <given-names>DB</given-names>
              </name>
              <collab>PULSAR Trial Investigators</collab>
            </person-group>
            <article-title>Sotatercept for the Treatment of Pulmonary Arterial Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>384</volume>
            <issue>13</issue>
            <fpage>1204</fpage>
            <page-range>1204-1215</page-range>
            <pub-id pub-id-type="pmid">33789009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Buist</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suveizdyte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liles</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Budas</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MacLean</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Apoptosis signal-regulating kinase 1 inhibition in <italic>in vivo</italic> and <italic>in vitro</italic> models of pulmonary hypertension.</article-title>
            <source>Pulm Circ</source>
            <year>2020</year>
            <season>Apr-Jun</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>2045894020922810</fpage>
            <pub-id pub-id-type="pmid">32523684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Rischard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gerhardt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Satler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>RP</given-names>
              </name>
              <collab>ARROW Study Group</collab>
            </person-group>
            <article-title>Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-46</page-range>
            <pub-id pub-id-type="pmid">34425071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers.</article-title>
            <source>Pulm Circ</source>
            <year>2020</year>
            <season>Apr-Jun</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>2045894020922814</fpage>
            <pub-id pub-id-type="pmid">32489643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ristic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shanahan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Escribano Sub&#x000ed;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31391223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144816.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Felix</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Schneck</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Milger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Voswinckel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schermuly</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grimminger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>957</fpage>
            <page-range>957-967</page-range>
            <pub-id pub-id-type="pmid">28302503</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
